21/04/2017 18:39:45

MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants

Hoersholm; April 21st 2017 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants the share capital has been increased by nominal DKK 6,190 and the number of shares has been increased with 123,800.

The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0.05.

Proceeds to the company are DKK 64,376.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,174,452 and will after the capital increase be DKK 1,180,642. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.

The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI

Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:

CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication

E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com

Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 21

st

2017.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Increases its share capital due to warrant exercise April 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medical Prognosis Institute via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
10 Dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
13 Dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
24
08 Dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 Dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 Dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 Dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 Dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
07 Dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
09 Dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 Dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Man Group PLC : Form 8.3 - [Ladbrokes Coral Group plc]

13/12/2017 15:01:16
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Alliance Trust PLC : Net Asset Value(s)

13/12/2017 13:04:49
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 12 December 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 791.0p -       including income, 794.4p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Investec Bank plc : Form 8.5 (EPT/RI) - Ladbrokes Coral Group plc

Related news
13/12/2017 09:50:50
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sanofi : Sanofi presents R&D strategy and innovative pipeline
2
Rovio Entertainment Corp.: Share subscriptions based on stock options 2012B, 2012BII and 2015A
3
MGX Minerals to Acquire Zinc Air Battery Developer ZincNyx Energy Solutions
4
Scatec Solar secures a 40 MW PV project in Malaysia
5
Vornado Announces Public Offering of $450 Million 3.5% 7-Year Senior Unsecured Notes due 2025 and Calls for Redemption its $450 Million 2.5% Senior Unsecured Notes due 2019 and Calls for Redemption the Remaining $120 Million of its 6.625% Series I Cumulat

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
14 December 2017 06:09:50
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB7 - 2017-12-14 07:09:50 - 2017-12-14 06:09:50 - 1000 - Website: OKAY